Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Are you considering a transition to a more plant based diet as part of your strategies for 2023? Jaqueline Rose, a dietician at Johns Hopkins, says it’s a worthy goal, and one that’s founded in history. Rose: The term ‘plant …
What does a plant-based diet include? Elizabeth Tracey reports Read more »
Podcast: Download (Duration: 1:02 — 1.4MB)
Subscribe: RSS
Moderna, the maker of Covid vaccines, is now reporting success with a vaccine for the skin cancer melanoma. Johns Hopkins Kimmel Cancer Center director William Nelson says these are made for individual patients using markers that are specific for their …
Podcast: Download (Duration: 1:03 — 1.4MB)
Subscribe: RSS
Women receiving radiation therapy for breast cancer can now have fewer treatments and may also be able to change the interval, a study presented at the San Antonio Breast Cancer Symposium shows. Kimmel Cancer Center director William Nelson at Johns …
Can radiation therapy be made less onerous? Elizabeth Tracey reports Read more »
Podcast: Download (Duration: 1:03 — 1.4MB)
Subscribe: RSS
Young women with breast cancer often state they’d like to have children at some point, yet after they’re treated their maintenance therapy may pose barriers. Now a study presented at the San Antonio Breast Cancer Symposium shows that pausing therapy …
Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Tumor infiltrating lymphocytes, known as TILS, allowed people with advanced melanoma, a serious type of skin cancer, to live longer than those who received an antibody alone, a recent study showed. Kimmel Cancer Center director William Nelson at Johns Hopkins …
Podcast: Download (Duration: 1:00 — 1.4MB)
Subscribe: RSS
So-called ‘bispecific antibodies,’ are racking up some impressive results when it comes to treating certain cancers, recent studies show. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins says making individualized antibodies for cancer treatment as well as …
The blood cancer multiple myeloma largely responds to a specially constructed antibody known as a BITE, for bispecific T cell engager, a recent study shows. Kimmel Cancer Center director William Nelson at Johns Hopkins describes the data. Nelson: In this …
Just how good is a specialized antibody for multiple myeloma? Elizabeth Tracey reports Read more »
